Eczema breakthrough: kids may be able to cut back on costly injections
NCT ID NCT06116526
First seen Jan 12, 2026 · Last updated May 23, 2026 · Updated 23 times
Summary
This study looks at whether children aged 1 to 17 with well-controlled eczema can safely take less dupilumab or stop it altogether. About 30 kids who have been on the drug for at least a year will be randomly assigned to reduce their dose or stop. The goal is to see if they can maintain good skin control without needing the full dose or other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Univerisity
RECRUITINGBaltimore, Maryland, 21210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.